ClinicalTrials.gg
CompletedNCT01473563Updated Oct 6, 2014Results posted

A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Pemetrexed in Nonsquamous Non-Small Cell Neoplasm of Lung, Non-Small Cell Lung Cancer Metastatic and Non-Small Cell Lung Cancer Stage IIIB, sponsored by Eli Lilly and Company. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-06.

Sponsored by Eli Lilly and Company · Phase 2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
118th of 223
52 · median 64
Started
2011
with 4 others
Phase 2
128 of 227
12 open now
Registered
115th of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 118th largest by enrollment of the 223 interventional ones that give a count, is one of 5 that started in 2011, is one of 128 in phase 2, and was the 115th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The main purpose for this study is to answer the following research questions:

  • Can pemetrexed be administered safely at the participant's home, using the same treatment procedure as in a hospital setting?
  • Will the participant be satisfied with home care?
  • How might this impact the participant's quality of life?
  • What are the required medical resources needed to give pemetrexed in a home setting?
03

Conditions studied

  • Nonsquamous Non-Small Cell Neoplasm of Lung
  • Non-Small Cell Lung Cancer Metastatic
  • Non-Small Cell Lung Cancer Stage IIIB
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a histological or cytological diagnosis of NSCLC defined as nonsquamous cell histology. Squamous cell and/or small cell histology is not permitted. Mixed NSCLC tumors will be categorized by the predominant cell type. NSCLC tumors that are not otherwise specified with regard to histology or cannot be subclassified as squamous, adenocarcinoma, or large cell histology will be categorized as nonsquamous
  • Have Stage IIIB (not amenable to curative treatment) or Stage IV NSCLC prior to induction therapy as defined by the American Joint Committee on Cancer (AJCC) Staging Criteria for Lung Cancer
  • Have completed 4 induction cycles of platinum-based doublet therapy (type at the discretion of the physician) for treatment of their advanced disease.
  • Have not progressed after 4 cycles of induction therapy. Documented radiographic evidence of a tumor response must occur at the end of Cycle 4 of induction therapy within 3 weeks before receiving the first cycle of study drug [see (RECIST), version (v) 1.1]
  • Receive on-study treatment no earlier than 21 days and no later than 42 days from Cycle 4 Day 1 of induction therapy
  • Have a Performance Status (PS) of 0 or 1 on the (ECOG) scale
  • Meet the following guidelines if the participant has received prior radiation therapy:

    • Previous radiation therapy is allowed to \<25% of the bone marrow, but should have been limited and must not have included whole pelvis radiation
    • Participants must have recovered from the toxic effects of the treatment prior to study enrollment (except for alopecia)
    • Participants who received palliative chest (in other words, thoracic skeleton including dorsal spine) or palliative extrathoracic radiotherapy to preexisting lesions are allowed to be enrolled in this trial
  • Have adequate organ function, including:

    • Adequate bone marrow reserve: (ANC) (segmented and bands) >=1.5x109/Liter (L), >=100x109/L, and >=9 grams per deciliter (g/dL)
    • Hepatic: \<=1.5 x (ULN) and alkaline phosphatase (ALP), (AST), and alanine aminotransferase (ALT) \<=3.0 x ULN (ALP, AST, and ALT \<=5.0 x ULN are acceptable if the liver has tumor involvement
    • Renal: calculated (CrCl) >=45 milliliters per minute (mL/min) based on the original weight-based Cockcroft and Gault formula
  • Are willing to comply with the following criteria:

    • Females must be surgically sterile, or must have a negative serum or urine pregnancy test within 7 days prior to the first dose of study drug
    • Males and females with : Must agree to use a reliable method of birth control during the study and for 6 months following the last dose of study drug
  • Have an estimated of at least 12 weeks
  • Have given written /assent prior to any study-specific procedures
  • Are willing to comply with home delivery administration and have family or close environment support willing to comply with home delivery administration

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an product or no approved use of a drug or device (other than pemetrexed used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have previously completed or withdrawn from this study
  • Have a serious concomitant systemic disorder (for example, active infection including )
  • Have a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the Class III or IV
  • Have symptomatic central nervous system (CNS) or (screening not required). Participants with treated are eligible for this study if they are not currently receiving and/or anticonvulsants for at least 1 week before starting study treatment and their disease is asymptomatic and radiographically stable
  • Are receiving concurrent administration of any other antitumor therapy
  • Have a second primary malignancy that in the judgment of the investigator and sponsor may affect the interpretation of results
  • Are unable to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than aspirin dose ≤1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam)
  • Are unable or unwilling to take folic acid or vitamin B12 supplementation
  • Are unable or unwilling to take corticosteroids
  • Are pregnant or lactating
  • Have received a recent (within 30 days of enrollment) or are receiving concurrent yellow fever vaccination
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Pemetrexed

    500 milligrams per square meter (mg/m\^2) pemetrexed administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle. Maintenance therapy administered until disease progression or the participant is discontinued for any other reason. The first dose of maintenance therapy will be administered at the hospital; thereafter, therapy will be administered in the home setting by qualified oncology homecare nurses.

    Drug: Pemetrexed

Interventions

  • Administered intravenously

    Also known as: LY231514, Alimta, Pemetrexed disodium, Pemetrexed sodium hydrate

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Adhered to Treatment Administration at Home

    Participants were considered adherent from the time of the first dose in Cycle 1 (hospital administration) until either the last day of the cycle when the participant reverted to pemetrexed hospital administration or the last day of the cycle when the participant discontinued study treatment or the study for reasons related to the home setting. The percentage of participants who adhered to treatment administration at home was estimated by a Kaplan-Meier survival analyses approach. Participants who died or discontinued the study and treatment without reverting to hospital administration were censored at the time of discontinuation.

    Time frame: Cycle 1, Day 1 through Cycle 19, Day 1 and Cycle 19, Day 1 (21 days/cycle)

Secondary outcomes

  1. Change From Baseline in the European Quality of Life Instrument (EQ-5D) Visual Analogue Scale (VAS)

    The EQ-5D scale was used to provide an estimate of the health state utility in this population. The EQ-5D scale includes a 5-dimensional descriptive system that measures each of the health state attributes: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression according to a 3-point scale (no problem, some problems, and major problems) and a VAS that allows participants to rate their present health condition from 0 (worst imaginable health state) to 100 (best imaginable health state). The change from baseline in EQ-5D VAS is reported.

    Time frame: Baseline, Day 1 of Cycles 2 and 4 (21 days/cycle) and 30 days post treatment discontinuation

  2. Change From Baseline in the EQ-5D Index Score

    The EQ-5D scale was used to provide an estimate of the health state utility in this population. The EQ-5D scale includes a 5-dimensional descriptive system that measures each of the health state attributes: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression according to a 3-point scale (no problem, some problems, and major problems) and a VAS that allows participants to rate their present health condition from 0 (worst imaginable health state) to 100 (best imaginable health state). The change from baseline EQ-5D Index score is reported and the EQ-5D Index score was calculated by converting health state scores into a weighted health state index according to a United Kingdom population-based algorithm. The possible values for the EQ-5D Index score range from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension), on a scale where 1 represents the best possible health state.

    Time frame: Baseline, Day 1 of Cycles 2 and 4 (21 days/cycle) and 30 days post treatment discontinuation

  3. Maximum Improvement Over Baseline in Individual Lung Cancer Symptoms Scale (LCSS) Item Scores

    LCSS is a 9-item questionnaire; 6 items are symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items describe overall symptomatic distress, interference with activity level, and overall quality of life during the past 24 hours. Participant responses were measured using a VAS with 100-millimeter (mm) lines. Scores ranged from 0 mm (no symptoms and no impact on activities, quality of life) to 100 mm (symptoms as bad as they could be, impacting activities and quality of life).

    Time frame: Baseline, Day 1 of each cycle (up to Cycle 19, 21 days/cycle), and 30 days post treatment discontinuation

  4. Participant Satisfaction: Chemotherapy at Hospital

    Participants were asked to evaluate their hospital experiences in this study by answering 4 questions (Q). Q1: "What do you consider advantages of having chemotherapy at the hospital? Choose all that apply." Choices included: "Support from other patients", "Access to other medical specialists", "Access to more technical services", "Safer in case something goes wrong", and "Other". Q2: "What do you consider disadvantages of having chemotherapy at the hospital? Choose all that apply." Choices included: "Need to travel", "Having to wait for treatment", "Not having a personalized treatment", "Lack of privacy on the ward", and "Other". Q3: "How would you rate your overall satisfaction with chemotherapy at the hospital?" and Q4: "How would you rate your overall satisfaction with the nursing staff during chemotherapy at the hospital?" Choices for Q3 and Q4 included: "Very dissatisfied", "Somewhat dissatisfied", "Neither satisfied nor dissatisfied", "Somewhat satisfied", or "Very satisfied".

    Time frame: The first evaluation completed at either Cycle 4, Day 1 (21 days/cycle) or 30 days post treatment discontinuation

  5. Participant Satisfaction: Chemotherapy at Home

    Participants were asked to evaluate their home treatment experiences in this study by answering 4 questions (Q). Q5: "What do you do consider advantages of having chemotherapy at home? Choose all that apply." Choices included: "No need to travel", "Not having to wait for treatment", "Personalized service", "More privacy", and "Other". Q6:"What do you consider disadvantages of having chemotherapy at home? Choose all that apply." Choices included: "Lack of other patients' support", "Extra burden for family/friends", "Safety concerns", "Need to rely on 1 medical specialist", and "Other". Q7: "How would you rate your overall satisfaction with chemotherapy at home?" Choices included: "Very dissatisfied", "Somewhat dissatisfied", "Neither satisfied nor dissatisfied", "Somewhat satisfied", or "Very satisfied".

    Time frame: The first evaluation completed at either Cycle 4, Day 1 (21 days/cycle) or 30 days post treatment discontinuation

  6. Participant Satisfaction: Regarding the Study Nurse

    Participants were asked 7 questions (Q) about their study nurse for home treatment. Q8: "Was the nurse an easy person to talk to?", Q9: "When the nurse came, did you feel he/she had enough time to do the required things?", Q10: "Do you think the nurse had time to discuss things with you?", Q11: "Did you feel that the nurse knew enough about you and your illness?" Choices for Q8 through Q11 included: "Yes" or "No". Q12: "Were you able to get all the information you wanted about your illness or treatment?" Choices included: "Yes", "No", or "Uncertain". Q13: "Would you say that the nurse gave..." Choices included: "a lot of reassurance and support", "some reassurance and support", or "hardly any reassurance and support". Q14: "How would you rate your overall satisfaction with the nursing staff during chemotherapy at home?" Choices included: "Very dissatisfied", "Somewhat dissatisfied", "Neither satisfied nor dissatisfied", "Somewhat satisfied", or "Very satisfied".

    Time frame: The first evaluation completed at either Cycle 4, Day 1 (21 days/cycle) or 30 days post treatment discontinuation

  7. Participant Satisfaction: Preferences Regarding Home and/or Hospital Treatment

    Participants were asked to evaluate their preferences regarding home and/or hospital treatment delivery in this study by answering 2 questions (Q). Q15: "Do you prefer having your chemotherapy at home or at the hospital, or are you indifferent?" Choices included: "Home", "Hospital", or "Indifferent". Q16: "Would you recommend having chemotherapy at home to someone else in your same situation?" Choices included: "Yes", "No", or "Not sure".

    Time frame: The first evaluation completed at either Cycle 4, Day 1 (21 days/cycle) or 30 days post treatment discontinuation

  8. Physician Satisfaction: Distant Management of Participant

    The physician was asked, "How would you rate your overall satisfaction with the distant management of the participant during chemotherapy at home?" Choices included: "Very dissatisfied", "Somewhat dissatisfied", "Neither satisfied nor dissatisfied", "Somewhat satisfied", or "Very satisfied".

    Time frame: 30 days post treatment discontinuation

  9. Resource Utilization: Number of Participants With an Unplanned Use of Healthcare Resources

    The number of participants who had at least 1 unplanned use of health care resources \[accident and emergency department (dept.), specialists \[oncologist, pulmonologist, etcetera (etc.)\], general practitioner (GP) or family doctor, or diagnostic procedures\] during the study is reported.

    Time frame: Cycle 1, Day 1 through last day of cycle when participant reverted to hospital administration or discontinued (up to Cycle 19, 21 days/cycle)

  10. Resource Utilization: Unplanned Health Care Visits, Consultations, and Diagnostic Services

    The unplanned use of any 1 of the following 4 resources is reported, as well as the unplanned use of each resource: accident and emergency dept., specialists (oncologist, pulmonologist etc.), GP or family doctor, and diagnostic procedures. Results are reported as the number of participants with an unplanned resource use (visit) for a specified number of times.

    Time frame: Cycle 1, Day 1 through last day of cycle when participant reverted to hospital administration or discontinued (up to Cycle 19, 21 days/cycle)

  11. Resource Utilization: Duration of Health Care Visits

    The duration of the health care visit in the home setting is reported. The visit started when the nurse arrived and included the entire treatment process. The visit ended when the nurse left the home setting. Due to the limited number of participants with evaluable data, results are reported for Cycles 2 through 4.

    Time frame: Cycle 2, Day 1 through last day of cycle when participant reverted to hospital administration or discontinued (up to Cycle 4, 21 days/cycle)

  12. Resource Utilization: Distances Traveled

    The distance traveled is reported by region (Great Britain and Sweden) and includes the distance traveled by the participant from his/her home to the hospital (Cycle 1) and other cycles where the homecare nurse traveled from the hospital to the participant's home. Due to the limited number of participants with evaluable data, results are reported for Cycles 1 through 4.

    Time frame: Cycle 1, Day 1 through last day of cycle when participant reverted to hospital administration or discontinued (up to Cycle 4, 21 days/cycle)

  13. Overall Survival (OS) at 6 Months

    The percentage of participants who were alive at Month 6 was calculated as a cumulative percentage by Kaplan-Meier survival analyses approach. For participants not known to have died as of the cut-off date, OS was censored as the last contact date (known alive).

    Time frame: Cycle 1, Day 1 to the date of death from any cause (up to Month 6)

  14. Time to Treatment Failure (TTF)

    The time from the date of the first dose of study treatment (Cycle 1, Day 1) to the date of death from any cause, PD (clinical and objective), or discontinuation of pemetrexed due to toxicity. Response was defined using RECIST, v1.1 criteria. PD was defined as having at least a 20% increase in the sum of the longest diameter of target lesions and at a minimum 5 mm increase above nadir. TTF was censored at the date of the last visit for participants who did not discontinue pemetrexed, who were still alive, and who had not progressed.

    Time frame: Cycle 1, Day 1 to first event (up to Cycle 19, 21 days/cycle)

Other outcomes

  1. Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Died

    The number of participants who had at least 1 TEAE or serious TEAE (regardless of causality) is reported along with the number of participants who died (due to any cause) while on therapy or during treatment discontinuation follow-up (up to 6 months). TEAEs started on or after the date and time of first dose of study drug, or started prior to study drug but worsened after study drug started. Clinically significant events were defined as SAEs and other non-serious adverse events (AEs). A summary of SAEs and other non-serious AEs is located in the Reported Adverse Events module.

    Time frame: First dose of study drug (Cycle 1, Day 1) through study completion [up to Cycle 19 (21 days/cycle) or treatment discontinuation, plus up to 6 months post treatment discontinuation]

07

Results

Posted Oct 6, 2014
Limitations and caveats
A thorough literature search revealed that no specific validated questionnaire was available to assess participant and physician satisfaction with home care or resource utilization, therefore specific questions were created by the sponsor for use.

Participant flow

Participant flow — Overall Study
MilestonePemetrexed
Started52
Received at least 1 dose of study drug52
Completed51
Not completed1
Withdrew: Lost to fu post tx discontinuation1

Outcome measures

PrimaryPercentage of Participants Who Adhered to Treatment Administration at Home

Participants were considered adherent from the time of the first dose in Cycle 1 (hospital administration) until either the last day of the cycle when the participant reverted to pemetrexed hospital administration or the last day of the cycle when the participant discontinued study treatment or the study for reasons related to the home setting. The percentage of participants who adhered to treatment administration at home was estimated by a Kaplan-Meier survival analyses approach. Participants who died or discontinued the study and treatment without reverting to hospital administration were censored at the time of discontinuation.

Time frame:
Cycle 1, Day 1 through Cycle 19, Day 1 and Cycle 19, Day 1 (21 days/cycle)
Reported as:
Number · percentage of participants
Percentage of Participants Who Adhered to Treatment Administration at Home
percentage of participantsPemetrexed
Cycle 1, Hospital Delivery100 (100 to 100)
Cycle 2, Home Delivery98.0 (86.4 to 99.7)
Cycle 3, Home Delivery98.0 (86.4 to 99.7)
Cycle 4, Home Delivery98.0 (86.4 to 99.7)
Cycle 5, Home Delivery98.0 (86.4 to 99.7)
Cycle 6, Home Delivery98.0 (86.4 to 99.7)
Cycle 7, Home Delivery90.7 (61.7 to 98.1)
Cycle 8, Home Delivery90.7 (61.7 to 98.1)
Cycle 9, Home Delivery90.7 (61.7 to 98.1)
Cycle 10, Home Delivery90.7 (61.7 to 98.1)
Cycle 11, Home Delivery90.7 (61.7 to 98.1)
Cycle 12, Home Delivery90.7 (61.7 to 98.1)
Cycle 13, Home Delivery90.7 (61.7 to 98.1)
Cycle 14, Home Delivery90.7 (61.7 to 98.1)
Cycle 15, Home Delivery90.7 (61.7 to 98.1)
Cycle 16, Home Delivery90.7 (61.7 to 98.1)
Cycle 17, Home Delivery90.7 (61.7 to 98.1)
Cycle 18, Home Delivery90.7 (61.7 to 98.1)
Cycle 19, Home Delivery90.7 (61.7 to 98.1)
SecondaryChange From Baseline in the European Quality of Life Instrument (EQ-5D) Visual Analogue Scale (VAS)

The EQ-5D scale was used to provide an estimate of the health state utility in this population. The EQ-5D scale includes a 5-dimensional descriptive system that measures each of the health state attributes: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression according to a 3-point scale (no problem, some problems, and major problems) and a VAS that allows participants to rate their present health condition from 0 (worst imaginable health state) to 100 (best imaginable health state). The change from baseline in EQ-5D VAS is reported.

Time frame:
Baseline, Day 1 of Cycles 2 and 4 (21 days/cycle) and 30 days post treatment discontinuation
Reported as:
Mean · units on a scale
Change From Baseline in the European Quality of Life Instrument (EQ-5D) Visual Analogue Scale (VAS)
units on a scalePemetrexed
Cycle 2 (n=34)3.0 ± 18.6
Cycle 4 (n=20)7.7 ± 21.7
30 days post treatment discontinuation (n=22)-0.9 ± 18.9
SecondaryChange From Baseline in the EQ-5D Index Score

The EQ-5D scale was used to provide an estimate of the health state utility in this population. The EQ-5D scale includes a 5-dimensional descriptive system that measures each of the health state attributes: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression according to a 3-point scale (no problem, some problems, and major problems) and a VAS that allows participants to rate their present health condition from 0 (worst imaginable health state) to 100 (best imaginable health state). The change from baseline EQ-5D Index score is reported and the EQ-5D Index score was calculated by converting health state scores into a weighted health state index according to a United Kingdom population-based algorithm. The possible values for the EQ-5D Index score range from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension), on a scale where 1 represents the best possible health state.

Time frame:
Baseline, Day 1 of Cycles 2 and 4 (21 days/cycle) and 30 days post treatment discontinuation
Reported as:
Mean · units on a scale
Change From Baseline in the EQ-5D Index Score
units on a scalePemetrexed
Cycle 2 (n=38)0.03 ± 0.22
Cycle 4 (n=23)0.08 ± 0.22
30 days post treatment discontinuation (n=26)-0.9 ± 0.28
SecondaryMaximum Improvement Over Baseline in Individual Lung Cancer Symptoms Scale (LCSS) Item Scores

LCSS is a 9-item questionnaire; 6 items are symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items describe overall symptomatic distress, interference with activity level, and overall quality of life during the past 24 hours. Participant responses were measured using a VAS with 100-millimeter (mm) lines. Scores ranged from 0 mm (no symptoms and no impact on activities, quality of life) to 100 mm (symptoms as bad as they could be, impacting activities and quality of life).

Time frame:
Baseline, Day 1 of each cycle (up to Cycle 19, 21 days/cycle), and 30 days post treatment discontinuation
Reported as:
Mean · mm
Maximum Improvement Over Baseline in Individual Lung Cancer Symptoms Scale (LCSS) Item Scores
mmPemetrexed
Loss of Appetite (n=43)16.3 ± 22.0
Fatigue (n=43)24.5 ± 27.2
Cough (n=41)9.2 ± 19.7
Dyspnea (n=41)17.2 ± 26.7
Hemoptysis (n=43)0.4 ± 4.3
Pain (n=40)11.8 ± 25.1
Overall Symptomatic Distress (n=43)8.3 ± 22.3
Interference With Activity Level (n=43)15.3 ± 25.1
Overall Quality of Life (n=41)12.2 ± 23.0
SecondaryParticipant Satisfaction: Chemotherapy at Hospital

Participants were asked to evaluate their hospital experiences in this study by answering 4 questions (Q). Q1: "What do you consider advantages of having chemotherapy at the hospital? Choose all that apply." Choices included: "Support from other patients", "Access to other medical specialists", "Access to more technical services", "Safer in case something goes wrong", and "Other". Q2: "What do you consider disadvantages of having chemotherapy at the hospital? Choose all that apply." Choices included: "Need to travel", "Having to wait for treatment", "Not having a personalized treatment", "Lack of privacy on the ward", and "Other". Q3: "How would you rate your overall satisfaction with chemotherapy at the hospital?" and Q4: "How would you rate your overall satisfaction with the nursing staff during chemotherapy at the hospital?" Choices for Q3 and Q4 included: "Very dissatisfied", "Somewhat dissatisfied", "Neither satisfied nor dissatisfied", "Somewhat satisfied", or "Very satisfied".

Time frame:
The first evaluation completed at either Cycle 4, Day 1 (21 days/cycle) or 30 days post treatment discontinuation
Reported as:
Number · participants
Participant Satisfaction: Chemotherapy at Hospital
participantsPemetrexed
Q1, Support from other patients8
Q1, Access to other medical specialists19
Q1, Access to more technical services12
Q1, Safer in case something goes wrong19
Q1, Other3
Q2, Need to travel36
Q2, Having to wait for treatment27
Q2, Not having a personalized treatment5
Q2, Lack of privacy on the ward7
Q2, Other1
Q3, Very dissatisfied0
Q3, Somewhat dissatisfied3
Q3, Neither satisfied nor dissatisfied3
Q3, Somewhat satisfied11
Q3, Very satisfied21
Q4, Very dissatisfied3
Q4, Somewhat dissatisfied0
Q4, Neither satisfied nor dissatisfied0
Q4, Somewhat satisfied3
Q4, Very satisfied32
SecondaryParticipant Satisfaction: Chemotherapy at Home

Participants were asked to evaluate their home treatment experiences in this study by answering 4 questions (Q). Q5: "What do you do consider advantages of having chemotherapy at home? Choose all that apply." Choices included: "No need to travel", "Not having to wait for treatment", "Personalized service", "More privacy", and "Other". Q6:"What do you consider disadvantages of having chemotherapy at home? Choose all that apply." Choices included: "Lack of other patients' support", "Extra burden for family/friends", "Safety concerns", "Need to rely on 1 medical specialist", and "Other". Q7: "How would you rate your overall satisfaction with chemotherapy at home?" Choices included: "Very dissatisfied", "Somewhat dissatisfied", "Neither satisfied nor dissatisfied", "Somewhat satisfied", or "Very satisfied".

Time frame:
The first evaluation completed at either Cycle 4, Day 1 (21 days/cycle) or 30 days post treatment discontinuation
Reported as:
Number · participants
Participant Satisfaction: Chemotherapy at Home
participantsPemetrexed
Q5, No need to travel37
Q5, Not having to wait for treatment27
Q5, Personalized service28
Q5, More privacy20
Q5, Other2
Q6, Lack of other patients' support5
Q6, Extra burden for family/friends1
Q6, Safety concerns4
Q6, Need to rely on 1 medical specialist7
Q6, Other19
Q7, Very dissatisfied1
Q7, Somewhat dissatisfied0
Q7, Neither satisfied nor dissatisfied2
Q7, Somewhat satisfied1
Q7, Very Satisfied30
SecondaryParticipant Satisfaction: Regarding the Study Nurse

Participants were asked 7 questions (Q) about their study nurse for home treatment. Q8: "Was the nurse an easy person to talk to?", Q9: "When the nurse came, did you feel he/she had enough time to do the required things?", Q10: "Do you think the nurse had time to discuss things with you?", Q11: "Did you feel that the nurse knew enough about you and your illness?" Choices for Q8 through Q11 included: "Yes" or "No". Q12: "Were you able to get all the information you wanted about your illness or treatment?" Choices included: "Yes", "No", or "Uncertain". Q13: "Would you say that the nurse gave..." Choices included: "a lot of reassurance and support", "some reassurance and support", or "hardly any reassurance and support". Q14: "How would you rate your overall satisfaction with the nursing staff during chemotherapy at home?" Choices included: "Very dissatisfied", "Somewhat dissatisfied", "Neither satisfied nor dissatisfied", "Somewhat satisfied", or "Very satisfied".

Time frame:
The first evaluation completed at either Cycle 4, Day 1 (21 days/cycle) or 30 days post treatment discontinuation
Reported as:
Number · participants
Participant Satisfaction: Regarding the Study Nurse
participantsPemetrexed
Q8, Yes37
Q8, No0
Q9, Yes36
Q9, No1
Q10, Yes37
Q10, No1
Q11, Yes36
Q11, No0
Q12, Yes34
Q12, No0
Q12, Uncertain3
Q13, Hardly any reassurance and support0
Q13, Some reassurance and support2
Q13, A lot of reassurance and support35
Q14, Very dissatisfied3
Q14, Somewhat dissatisfied0
Q14, Neither satisfied nor dissatisfied1
Q14, Somewhat satisfied1
Q14, Very satisfied33
SecondaryParticipant Satisfaction: Preferences Regarding Home and/or Hospital Treatment

Participants were asked to evaluate their preferences regarding home and/or hospital treatment delivery in this study by answering 2 questions (Q). Q15: "Do you prefer having your chemotherapy at home or at the hospital, or are you indifferent?" Choices included: "Home", "Hospital", or "Indifferent". Q16: "Would you recommend having chemotherapy at home to someone else in your same situation?" Choices included: "Yes", "No", or "Not sure".

Time frame:
The first evaluation completed at either Cycle 4, Day 1 (21 days/cycle) or 30 days post treatment discontinuation
Reported as:
Number · participants
Participant Satisfaction: Preferences Regarding Home and/or Hospital Treatment
participantsPemetrexed
Q15, Home33
Q15, Hospital0
Q15, Indifferent5
Q16, Yes37
Q16, No0
Q16, Not sure0
SecondaryPhysician Satisfaction: Distant Management of Participant

The physician was asked, "How would you rate your overall satisfaction with the distant management of the participant during chemotherapy at home?" Choices included: "Very dissatisfied", "Somewhat dissatisfied", "Neither satisfied nor dissatisfied", "Somewhat satisfied", or "Very satisfied".

Time frame:
30 days post treatment discontinuation
Reported as:
Number · investigators
Physician Satisfaction: Distant Management of Participant
investigatorsPemetrexed
Very Dissatisfied2
Somewhat Dissatisfied1
Neither Satisfied Nor Dissatisfied0
Somewhat Satisfied8
Very Satisfied20
SecondaryResource Utilization: Number of Participants With an Unplanned Use of Healthcare Resources

The number of participants who had at least 1 unplanned use of health care resources \[accident and emergency department (dept.), specialists \[oncologist, pulmonologist, etcetera (etc.)\], general practitioner (GP) or family doctor, or diagnostic procedures\] during the study is reported.

Time frame:
Cycle 1, Day 1 through last day of cycle when participant reverted to hospital administration or discontinued (up to Cycle 19, 21 days/cycle)
Reported as:
Number · participants
Resource Utilization: Number of Participants With an Unplanned Use of Healthcare Resources
participantsPemetrexed
Resource Utilization: Number of Participants With an Unplanned Use of Healthcare Resources29
SecondaryResource Utilization: Unplanned Health Care Visits, Consultations, and Diagnostic Services

The unplanned use of any 1 of the following 4 resources is reported, as well as the unplanned use of each resource: accident and emergency dept., specialists (oncologist, pulmonologist etc.), GP or family doctor, and diagnostic procedures. Results are reported as the number of participants with an unplanned resource use (visit) for a specified number of times.

Time frame:
Cycle 1, Day 1 through last day of cycle when participant reverted to hospital administration or discontinued (up to Cycle 19, 21 days/cycle)
Reported as:
Number · participants
Resource Utilization: Unplanned Health Care Visits, Consultations, and Diagnostic Services
participantsPemetrexed
1 Unplanned Visit, Any Resource8
2 Unplanned Visits, Any Resource6
3 Unplanned Visits, Any Resource5
4 Unplanned Visits, Any Resource2
5 Unplanned Visits, Any Resource3
9 Unplanned Visits, Any Resource1
10 Unplanned Visits, Any Resource1
13 Unplanned Visits, Any Resource1
1 Unplanned Visit, Accident and Emergency Dept.7
2 Unplanned Visits, Accident and Emergency Dept.2
3 Unplanned Visits, Accident and Emergency Dept.2
1 Unplanned Visit, Specialist9
2 Unplanned Visits, Specialist3
5 Unplanned Visits, Specialist1
1 Unplanned Visit, GP or Family Doctor6
2 Unplanned Visits, GP or Family Doctor3
3 Unplanned Visits, GP or Family Doctor2
4 Unplanned Visits, GP or Family Doctor3
1 Unplanned Visit, Diagnostic procedures6
2 Unplanned Visits, Diagnostic procedures2
3 Unplanned Visits, Diagnostic procedures3
4 Unplanned Visits, Diagnostic procedures1
Other pre-specifiedNumber of Participants Who Had Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Died

The number of participants who had at least 1 TEAE or serious TEAE (regardless of causality) is reported along with the number of participants who died (due to any cause) while on therapy or during treatment discontinuation follow-up (up to 6 months). TEAEs started on or after the date and time of first dose of study drug, or started prior to study drug but worsened after study drug started. Clinically significant events were defined as SAEs and other non-serious adverse events (AEs). A summary of SAEs and other non-serious AEs is located in the Reported Adverse Events module.

Time frame:
First dose of study drug (Cycle 1, Day 1) through study completion [up to Cycle 19 (21 days/cycle) or treatment discontinuation, plus up to 6 months post treatment discontinuation]
Reported as:
Number · participants
Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Died
participantsPemetrexed
At least 1 TEAE51
At least 1 Serious TEAE21
Death, AE (fell, multiple injuries)1
Death, Study Drug Toxicity (atypical pneumonia)1
Death, Study Disease26
SecondaryResource Utilization: Duration of Health Care Visits

The duration of the health care visit in the home setting is reported. The visit started when the nurse arrived and included the entire treatment process. The visit ended when the nurse left the home setting. Due to the limited number of participants with evaluable data, results are reported for Cycles 2 through 4.

Time frame:
Cycle 2, Day 1 through last day of cycle when participant reverted to hospital administration or discontinued (up to Cycle 4, 21 days/cycle)
Reported as:
Mean · hours
Resource Utilization: Duration of Health Care Visits
hoursPemetrexed
Cycle 2 (n=42)1.67 ± 0.493
Cycle 3 (n=35)1.66 ± 0.683
Cycle 4 (n=28)1.57 ± 0.311
SecondaryResource Utilization: Distances Traveled

The distance traveled is reported by region (Great Britain and Sweden) and includes the distance traveled by the participant from his/her home to the hospital (Cycle 1) and other cycles where the homecare nurse traveled from the hospital to the participant's home. Due to the limited number of participants with evaluable data, results are reported for Cycles 1 through 4.

Time frame:
Cycle 1, Day 1 through last day of cycle when participant reverted to hospital administration or discontinued (up to Cycle 4, 21 days/cycle)
Reported as:
Mean · kilometers (km)
Resource Utilization: Distances Traveled
kilometers (km)Pemetrexed
Cycle 1, Home to Hospital, Great Britain (n=25)19.7 ± 23.39
Cycle 1, Home to Hospital, Sweden (n=7)30.7 ± 23.08
Cycle 2, Hospital to Home, Great Britain (n=24)15.5 ± 13.12
Cycle 2, Hospital to Home, Sweden (n=7)23.9 ± 23.93
Cycle 3, Hospital to Home, Great Britain (n=11)23.8 ± 16.72
Cycle 3, Hospital to Home, Sweden (n=4)17.5 ± 17.97
Cycle 4, Hospital to Home, Great Britain (n=7)11.7 ± 8.75
Cycle 4, Hospital to Home, Sweden (n=2)24.5 ± 27.58
SecondaryOverall Survival (OS) at 6 Months

The percentage of participants who were alive at Month 6 was calculated as a cumulative percentage by Kaplan-Meier survival analyses approach. For participants not known to have died as of the cut-off date, OS was censored as the last contact date (known alive).

Time frame:
Cycle 1, Day 1 to the date of death from any cause (up to Month 6)
Reported as:
Number · percentage of participants
Overall Survival (OS) at 6 Months
percentage of participantsPemetrexed
Overall Survival (OS) at 6 Months73 (58.1 to 82.8)
SecondaryTime to Treatment Failure (TTF)

The time from the date of the first dose of study treatment (Cycle 1, Day 1) to the date of death from any cause, PD (clinical and objective), or discontinuation of pemetrexed due to toxicity. Response was defined using RECIST, v1.1 criteria. PD was defined as having at least a 20% increase in the sum of the longest diameter of target lesions and at a minimum 5 mm increase above nadir. TTF was censored at the date of the last visit for participants who did not discontinue pemetrexed, who were still alive, and who had not progressed.

Time frame:
Cycle 1, Day 1 to first event (up to Cycle 19, 21 days/cycle)
Reported as:
Median · months
Time to Treatment Failure (TTF)
monthsPemetrexed
Time to Treatment Failure (TTF)3.0 (2.3 to 4.2)

Adverse events

Collected over Baseline through study completion [up to Cycle 19 (21 days/cycle) or treatment discontinuation, plus up to 6 months post treatment discontinuation]. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed—23/52 (44.2%)51/52 (98.1%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventPemetrexed
DyspnoeaRespiratory, thoracic and mediastinal disorders4/52
Lower respiratory tract infectionInfections and infestations3/52
FallInjury, poisoning and procedural complications3/52
AnaemiaBlood and lymphatic system disorders2/52
Chest painGeneral disorders2/52
PneumoniaInfections and infestations2/52
Back painMusculoskeletal and connective tissue disorders2/52
ThrombocytopeniaBlood and lymphatic system disorders1/52
Atrial flutterCardiac disorders1/52
Cardiac arrestCardiac disorders1/52
Most frequent other events
Showing 10 of 34
Most frequent other events
EventPemetrexed
FatigueGeneral disorders20/52
NauseaGastrointestinal disorders17/52
AnaemiaBlood and lymphatic system disorders12/52
CoughRespiratory, thoracic and mediastinal disorders12/52
Decreased appetiteMetabolism and nutrition disorders9/52
Back painMusculoskeletal and connective tissue disorders9/52
LethargyNervous system disorders9/52
DyspnoeaRespiratory, thoracic and mediastinal disorders9/52
ConstipationGastrointestinal disorders8/52
HeadacheNervous system disorders8/52

Baseline characteristics

Safety Population: Participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Pemetrexed
Median66.0 ± 12.05
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed
Female26
Male26
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pemetrexed
White48
Black or African American4
Region of Enrollment
Region of Enrollment(participants)Pemetrexed
United Kingdom43
Sweden9
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Pemetrexed
0: Fully Active14
1: Restricted38
Most Recent Pathological Diagnosis
Most Recent Pathological Diagnosis(participants)Pemetrexed
Adenocarcinoma, Lung48
Adenocarcinoma, Mucinous, No Other Symptoms (NOS)1
Adenocarcinoma, Moderately Differentiated, Lung1
Carcinoma, Non-Small Cell, Lung NOS2
Basis for Most Recent Pathological Diagnosis
Basis for Most Recent Pathological Diagnosis(participants)Pemetrexed
Cytological10
Histopathological42
Stage of Disease
Stage of Disease(participants)Pemetrexed
Stage IIIB3
Stage IV48
Stage IIIA1

2 further baseline measures are reported on the registry.

08

Study locations

9 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Linkoping, 58185, Sweden
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Solna, 17176, Sweden
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, Greater London SE1 9RT, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Maidstone, Kent ME16 9QQ, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nottingham, Nottinghamshire NG5 1PD, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aberdeen, Scotland AB25 2ZN, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Huddersfield, West Yorkshire HD3 3EA, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Birmingham, B95SS, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Lal R, Bourayou N, Hillerdal G, Nicolson M, Vikstrom A, Lorenzo M, D'yachkova Y, Barriga S, Visseren-Grul C. Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design. Health Qual Life Outcomes. 2013 Oct 3;11:163. doi: 10.1186/1477-7525-11-163. PubMed 24090033 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2011
First posted
Nov 17, 2011
Start
Dec 2011
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Results first posted
Oct 6, 2014
Last update
Oct 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01473563
Responsible party
Sponsor
First posted
Nov 17, 2011
Start date
Dec 2011
Primary completion
Sep 2013
Completion
Sep 2013
Results posted
Oct 6, 2014
Last update
Oct 6, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion